# Immunotherapy Study for Patients With Stage IV Melanoma

> **NCT02054520** · PHASE2 · TERMINATED · sponsor: **NewLink Genetics Corporation** · enrollment: 47 (actual)

## Conditions studied

- Stage IV Melanoma
- Metastatic Melanoma

## Interventions

- **DRUG:** HyperAcute®-Melanoma (HAM) Immunotherapy
- **DRUG:** Ipilimumab
- **DRUG:** Pembrolizumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02054520
- **Lead sponsor:** NewLink Genetics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06
- **Primary completion:** 2018-04-05
- **Final completion:** 2021-01-05
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Withdrawal of IND
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02054520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02054520, "Immunotherapy Study for Patients With Stage IV Melanoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02054520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*